JDS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Interpretive Summary
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jarvie, B. D.
Right arrow Articles by Peregrine, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jarvie, B. D.
Right arrow Articles by Peregrine, A. S.
J. Dairy Sci. 88:1801-1806
© American Dairy Science Association, 2005.

Effect of Halofuginone Lactate on the Occurrence of Cryptosporidium parvum and Growth of Neonatal Dairy Calves

B. D. Jarvie1, L. A. Trotz-Williams1, D. R. McKnight2, K. E. Leslie1, M. M. Wallace1, C. G. Todd2, P. H. Sharpe2 and A. S. Peregrine3

1 Department of Population Medicine, Ontario Veterinary College, University of Guelph Ontario, Canada, N1G 2W1
2 Kemptville College, University of Guelph, Box 2003, Kemptville Ontario, Canada, KOG 1JO
3 Department of Pathobiology, Ontario Veterinary College, University of Guelph Ontario, Canada, N1G 2W1

Corresponding author: K. E. Leslie; e-mail: keleslie{at}uoguelph.ca.

Thirty-one Holstein bull calves were purchased at birth from 3 dairy farms in Eastern Ontario. Each calf was assigned at random to oral treatment with either 5 mg of halofuginone lactate in 10.0 mL of aqueous carrier solution (Halocur, base comprised 10 mg of benzoic acid, 100 mg of lactic acid, and 0.3 mg of tartrazine) or 10 mL of placebo (Halocur base minus the active ingredient, halofuginone lactate) administered 15 to 30 min after morning milk feeding for the first 7 d of life. Intakes of milk, calf starter, and water, and fecal consistency score were recorded daily for 56 d. Calf weights were recorded weekly for 56 d. Fecal samples were taken from all calves at approximately 2, 7, 14, 21, and 28 d of age for isolation of Cryptosporidium parvum oocysts. Logistic and linear regression analyses were used to assess the effect of treatment on the incidence of diarrhea and C. parvum infection status. The odds of C. parvum shedding among calves in the halofuginone lactate-treated group was 70% lower than the odds of shedding among calves in the placebo group. In calves treated with halofuginone lactate, no oocyst shedding occurred until 2 wk of age, whereas 12.5% of calves in the placebo group began shedding oocysts during wk 1. From all ages of placebo-treated calves, 31 of 73 samples (42.5%) were positive for C. parvum, whereas only 15 of 67 samples (22.4%) from all ages of halofuginone lactate-treated calves tested positive. The largest number of C. parvum-positive samples occurred in the third week of life. There was a significant delay of 3.1 d in the incidence of diarrhea among calves treated with halofuginone lactate. Intake of milk and starter, body weight gains, and age at weaning were not significantly different between treatment groups.

Key Words: cryptosporidiosis • diarrhea • halofuginone lactate • neonatal calf

Abbreviation key: HL = halofuginone lactate-treated, PC = placebo-treated




This article has been cited by other articles:


Home page
J DAIRY SCIHome page
T. L. Ollivett, D. V. Nydam, D. D. Bowman, J. A. Zambriski, M. L. Bellosa, T. C. Linden, and T. J. Divers
Effect of nitazoxanide on cryptosporidiosis in experimentally infected neonatal dairy calves
J Dairy Sci, April 1, 2009; 92(4): 1643 - 1648.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Dairy Science Association ®.